AL

Arthur Lefort

Industrial Affairs Project Manager at Stragen

Arthur Lefort is currently working as an Industrial Affairs Project Manager at Stragen, where Arthur manages technical aspects of Critical Care products, interfaces with manufacturers and clients, and oversees product lifecycle management. Prior to this, Arthur held roles such as Responsable Projet QA/CMC at DIVERCHIM, Assistant Parfumeur/Responsable de Laboratoire at FRAGRANCES ESSENTIELLES, and Chef de Projet R&D at Sentosphère. With a background in Chemistry and Physics, Arthur has experience in various areas including quality assurance, regulatory compliance, technical transfer, and project management.

Location

Lyon, France

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Stragen

Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.